Have a feature idea you'd love to see implemented?
Let us know!
GLUE Monte Rosa Therapeutics Inc
Price (delayed)
$8.35
Market cap
$513M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.82
Enterprise value
$426.21M
Highlights
Monte Rosa Therapeutics's revenue has surged by 160% QoQ
The gross profit has surged by 160% since the previous quarter
The equity rose by 11% year-on-year but it has declined by 9% since the previous quarter
The quick ratio has declined by 25% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of GLUE
Market
Valuations
Earnings
Shares outstanding
61.44M
Market cap
$513M
Enterprise value
$426.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.49
Price to sales (P/S)
45.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.46
Revenue
$14.98M
EBIT
-$119.01M
EBITDA
-$111.1M
Free cash flow
-$62.79M
Per share
Balance sheet
Liquidity
EPS
-$1.82
Free cash flow per share
-$0.77
Book value per share
$3.35
Revenue per share
$0.18
TBVPS
$3.84
Total assets
$315.08M
Total liabilities
$109.62M
Debt
$43.7M
Equity
$205.46M
Working capital
$209.57M
Debt to equity
0.21
Current ratio
6.03
Quick ratio
5.95
Net debt/EBITDA
0.78
Margins
Efficiency
Dividend
EBITDA margin
-741.9%
Gross margin
100%
Net margin
-797.3%
Operating margin
-861.3%
Return on assets
-38.8%
Return on equity
-62.7%
Return on invested capital
-63%
Return on capital employed
-43.5%
Return on sales
-794.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLUE stock price
How has the Monte Rosa Therapeutics stock price performed over time
Intraday
-0.12%
1 week
-1.53%
1 month
53.21%
1 year
180.2%
YTD
47.79%
QTD
57.55%
Financial performance
How have Monte Rosa Therapeutics's revenue and profit performed over time
Revenue
$14.98M
Gross profit
$14.98M
Operating income
-$128.98M
Net income
-$119.39M
Gross margin
100%
Net margin
-797.3%
Monte Rosa Therapeutics's revenue has surged by 160% QoQ
The gross profit has surged by 160% since the previous quarter
The net margin has surged by 65% since the previous quarter
The operating margin has surged by 64% since the previous quarter
Growth
What is Monte Rosa Therapeutics's growth rate over time
Valuation
What is Monte Rosa Therapeutics stock price valuation
P/E
N/A
P/B
2.49
P/S
45.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.46
Monte Rosa Therapeutics's EPS has increased by 32% YoY and by 18% from the previous quarter
GLUE's P/B is 56% above its last 4 quarters average of 1.6
The equity rose by 11% year-on-year but it has declined by 9% since the previous quarter
Monte Rosa Therapeutics's revenue has surged by 160% QoQ
Efficiency
How efficient is Monte Rosa Therapeutics business performance
Monte Rosa Therapeutics's ROS has soared by 65% from the previous quarter
The ROIC has contracted by 27% YoY but it has grown by 4.7% from the previous quarter
Monte Rosa Therapeutics's ROA has increased by 14% YoY and by 13% from the previous quarter
GLUE's ROE is up by 11% since the previous quarter but it is down by 8% year-on-year
Dividends
What is GLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLUE.
Financial health
How did Monte Rosa Therapeutics financials performed over time
GLUE's total assets is 187% greater than its total liabilities
The total liabilities has surged by 62% year-on-year but it has declined by 8% since the previous quarter
The company's current ratio fell by 25% YoY and by 8% QoQ
The debt is 79% smaller than the equity
The debt to equity has contracted by 16% YoY but it has grown by 5% from the previous quarter
The equity rose by 11% year-on-year but it has declined by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.